Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer

Cancer Gene Therapy volume 19, pages 374–381 (2012)Cite this article

Subjects

Abstract

BC-819 is a DNA plasmid that was developed to target the expression of diphtheria-toxin gene under the control of H19 regulatory sequences. BC-819 has the potential to treat pancreatic cancer that overexpresses the H19 gene. The objectives were to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of BC-819 administered intratumorally in subjects with unresectable, locally advanced, non-metastatic pancreatic cancer. Nine patients with unresectable pancreatic adenocarcinoma were enrolled in an open-label, dose-escalation trial. Subjects were entered into one out of two cohorts with escalating doses of BC-819. Each cohort received 2 weeks of twice weekly intratumoral injection of BC-819 under computerized tomography (CT) (n=3) or endoscopic ultrasound (EUS) (n=6) guidance. Patients were assessed by CT or positron emission tomography (PET)/CT during week 4 for tumor response. The maximum tolerated dose of BC-819 was not reached in this study at the highest dose. Asymptomatic elevation of lipase, which was considered as an adverse event with dose-limiting toxicity, occurred in only one subject in the high-dose group and was resolved spontaneously. The tumors did not increase in size 4 weeks after initiating treatment. Two weeks after completing the treatment, the two subjects who went on to receive subsequent chemotherapy or chemoradiation therapy, pancreatic tumors were downstaged and considered surgically resectable. Remarkably, three of the six subjects in cohort no. 2 evaluated at month 3 had a partial response. BC-819 can be safely administered intratumorally via EUS- or CT-guided injection at a dose of at least 8 mg per injection weekly twice. BC-819 given locally in combination with systemic chemotherapy may provide an additional therapeutic benefit for the treatment of pancreatic cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

    Article  PubMed  Google Scholar 

  2. El-Kamar FG, Grossbard ML, Kozuch PS . Metastatic pancreatic, cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003; 8: 18–34.

    Article  CAS  PubMed  Google Scholar 

  3. Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K et al. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 1998; 82: 1649–1656.

    Article  CAS  PubMed  Google Scholar 

  4. American Joint Committee on Cancer Classification. Cancer Staging Manual. edn. American Joint Committee on Cancer Classification ISBN: 0-387-95270-5.

  5. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19: 4202–4208.

    Article  CAS  PubMed  Google Scholar 

  6. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.

    Article  CAS  PubMed  Google Scholar 

  7. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.

    Article  CAS  PubMed  Google Scholar 

  8. Hazard L . The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res 2009; 3: 20–28.

    PubMed  PubMed Central  Google Scholar 

  9. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Gallula J et al. Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J Oncol 2010; 2010: 178174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mizrahi A, Czerniak A, Levy T, Amiur S, Gallula J, Matouk I et al. Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences. J Transl Med 2009; 7: 69.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sidi A, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 overexpressing superficial bladder cancer refractory to bacillus calmette guerin. J Urol 2008; 180: 2379–2383.

    Article  PubMed  Google Scholar 

  12. Erdmann VA, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N, Barciszewski J . The non-coding RNAs as riboregulators. Nucleic Acids Res 2001; 29: 189–193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ariel I, Lustig O, Schneider T, Pizov G, Sappir M, De-Groot N et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995; 45: 335–338.

    Article  CAS  PubMed  Google Scholar 

  14. Ariel I, Ayesh S, Perlman EJ, Pizov G, Tanos V, Schneider T et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol 1997; 50: 34–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol 1998; 51: 21–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A . Parental imprinting of the human H19 gene. FEBS Lett 1992; 309: 25–28.

    Article  CAS  PubMed  Google Scholar 

  17. Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W et al. Possible physiological role of H19 RNA. Mol Carcinog 2002; 35: 63–74.

    Article  CAS  PubMed  Google Scholar 

  18. Matouk I, deGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A et al. The H19 non-coding RNA is essential for human tumor growth. PloS ONE 2007; 2: e845.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225–239.

    Article  CAS  PubMed  Google Scholar 

  20. Matouk I, Mazan S, Mizrahi A, Ohana P, Abu-lail R, Fellig Y et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010; 1803: 443–451.

    Article  CAS  PubMed  Google Scholar 

  21. Pieper-Bigelow C, Strocchi A, Levitt MD . Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19: 793–810.

    CAS  PubMed  Google Scholar 

  22. Gress F, Michael H, Gelrud D, Patel P, Gottlieb K, Singh F et al. EUS-guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc 2002; 56: 864–867.

    Article  PubMed  Google Scholar 

  23. Fernandez-Esparrach G, Gines A, Garcia P, Pellisé M, Solé M, Cortés P et al. Incidence and clinical significance of hyperamylasemia afer EUS FNA of pancreatic lesions: a prospective and controlled study. Endoscopy 2007; 39: 720–724.

    Article  CAS  PubMed  Google Scholar 

  24. Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I et al. Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Reports 2010; 4: 228–231.

    Article  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by BioCancell Therapeutic, Ltd., Israel.

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Maryland School of Medicine, Baltimore, MD, USA,

    N Hanna

  2. Department of Biological Chemistry, Institute of Life Sciences, Jerusalem, Israel

    P Ohana & A Hochberg

  3. Department of Gastroenterology, Meir Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba, Israel

    F M Konikoff & G Leichtmann

  4. Department of Oncology, Hadassah Medical Center, University Hospital, Jerusalem, Israel

    A Hubert

  5. Department of Radiology and Medical Imaging, Hadassah Medical Center, University Hospital, Jerusalem, Israel

    L Appelbaum

  6. Department of Gastroenterology Hillel Yaffe Medical Center, Hadera, Israel

    Y Kopelman

  7. Department of HPB Surgery ‘A’, Sheba Medical Center, Tel Hashomer, Israel

    A Czerniak

Authors
  1. N Hanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Ohana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F M Konikoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Leichtmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Hubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Appelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Kopelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Czerniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Hochberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N Hanna.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanna, N., Ohana, P., Konikoff, F. et al. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther 19, 374–381 (2012). https://doi.org/10.1038/cgt.2012.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2012.10

Keywords

This article is cited by

Search

Advanced search

Quick links